Chromosomal Resistance to Metronidazole in Clostridioides difficile Can Be Mediated by Epistasis between Iron Homeostasis and Oxidoreductases Original paper
Researched by:
-
Divine Aleru
ID
Divine Aleru
I am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
-
Divine Aleru
Researched by:
-
Divine Aleru
ID
Divine Aleru
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
What Was Studied?
This study investigated the chromosomal resistance mechanisms to metronidazole in Clostridioides difficile, specifically examining how iron homeostasis and oxidoreductase activity contribute to the emergence of resistance. It focused on identifying genetic mutations associated with resistance and their effects on metronidazole’s mechanism of action, including mutations in FeoB1, PFOR, xdh, and IscR.
Who Was Studied?
The study focused on clinical strains of C. difficile, which are known to cause Clostridioides difficile infection (CDI). These strains were evolved under selective pressure to develop resistance to metronidazole, and the resulting resistant mutants were analyzed for genetic and biochemical changes.
What Were the Most Important Findings?
The study revealed that chromosomal resistance to metronidazole in C. difficile is complex and involves multiple genetic mutations. A key finding was the role of the FeoB1 iron transporter, whose deletion led to low-level resistance. This mutation decreased intracellular iron content, shifting cells toward less effective electron transfer mechanisms mediated by flavodoxin, rather than ferredoxin, which is more effective in activating metronidazole. Further mutations in pyruvate-ferredoxin/flavodoxin oxidoreductase (PFOR), xanthine dehydrogenase (xdh), and the iron-sulfur cluster regulator (IscR) were identified as contributing to higher-level resistance.
Mutations in these genes led to decreased redox activity, impaired metronidazole activation, and overall reduced susceptibility to the drug. The interaction between FeoB1 and these oxidoreductase-related mutations demonstrated an epistatic mechanism for resistance, where the loss of FeoB1 facilitated the evolution of resistance pathways involving these genes. The study also found that the silencing of these genes via CRISPR interference reduced resistance, confirming their roles in metronidazole resistance.
What Are the Greatest Implications of This Study?
The implications of this study are significant for understanding how C. difficile develops resistance to metronidazole, a key antibiotic used for treating CDI. The discovery of multiple genetic pathways involved in resistance highlights the need for new therapeutic strategies to overcome resistance in clinical settings. Furthermore, the study suggests that targeting the iron uptake pathways (such as FeoB1) and related metabolic processes could offer novel avenues for enhancing metronidazole efficacy or developing new treatments. Clinicians and researchers must consider the interplay between iron metabolism, redox processes, and drug resistance when developing therapeutic strategies for C. difficile infections, particularly in the context of rising antimicrobial resistance.